It is currently Mon Dec 22, 2014 1:11 am

News News of Campath (Lemtrada, Alemtuzumab)

Site map of Campath (Lemtrada, Alemtuzumab) » Forum : Campath (Lemtrada, Alemtuzumab)

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Oral MS drug Lemtrada approved by European Commission

Genzyme, a Sanofi company announced today that the European Commission has granted marketing authorization for Lemtrada(TM). This follows the August 30th approval of Aubagio(R). The company intends to begin launching both products in the EU soon.

"The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients," said Genzyme CEO and President, David Meeker, M.D. "This is ...
Read more : Oral MS drug Lemtrada approved by European Commission | Views : 1056 | Replies : 1


Got all it's gonna give me

I went to my neuro clinic for my monthly blood draw. The trial coordinator asked me how I was doing since my last dose of alemtuzumab (it's been over a year and I've dosed four times in total). I told her that I was slowly declining and she said that I should begin to look at other treatment options, that alemtuzumab had done all its going to do for me. I can continue and should ...
Read more : Got all it's gonna give me | Views : 1409 | Replies : 1


Genzyme receives positive CHMP opinion for Lemtrada™

Genzyme receives positive CHMP opinion for Lemtrada™ (alemtuzumab) in Europe

CHMP also Recommends NAS Designation for Aubagio® (teriflunomide) Following Positive Opinion on Approval in March 2013

Genzyme announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Lemtrada™ (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging ...
Read more : Genzyme receives positive CHMP opinion for Lemtrada™ | Views : 1036 | Replies : 0


Mechanism found for Alemtuzumab side effect

Researchers think they may have figured out why a drug that is highly effective against one autoimmune disease can sometimes trigger another.... Read More - http://www.ms-uk.org/index.cfm/lemtrada
Read more : Mechanism found for Alemtuzumab side effect | Views : 1283 | Replies : 1


Infusion duration

I have a simple question for anyone that has been on Lemtrada. How long does each individual
infusion take? Is it about an hour or all day?

I just stopped Tysabri after 73 infusions (JCV+). I am waiting for my Tecfidera script to get here.

I like to stay current with what new treatments are coming.
Nothing looks more promising than Lematrada to me. 5 infusions then a year later 3 more.
If I understand ...
Read more : Infusion duration | Views : 1226 | Replies : 1


Genzyme boasts of durable response to MS drug Lemtrada

Genzyme boasts of durable response to MS drug Lemtrada

Looking ahead to a prospective FDA approval of its experimental multiple sclerosis drug Lemtrada and a new product launch into a competitive and fast-changing market, Genzyme executives today rolled out positive data from a one-year extension study of its pivotal Phase III trial that gives the company some boasting rights for a drug that demonstrated a durable response in most patients..... Read More - http://www.ms-uk.org/index.cfm/lemtrada
Read more : Genzyme boasts of durable response to MS drug Lemtrada | Views : 1404 | Replies : 2


Alemtuzumab lessens relapses, improves disability in MS

Alemtuzumab lessens relapses, improves disability in MS - studies

Image

Two new trials offer proof that a leukemia drug long used to treat multiple sclerosis works better than a common treatment.

When compared with the widely used drug interferon beta, the leukemia drug alemtuzumab reduced relapse rates by half, researchers say.

Alemtuzumab Reverses Disability in Some

Alemtuzumab has been used to treat MS for close to two decades, but it has never been approved for ...
Read more : Alemtuzumab lessens relapses, improves disability in MS | Views : 2165 | Replies : 3


FDA refuse to file letter

The FDA have sent Genzyme/Sanofi a refuse to file letter. They're not asking for more trials, just for more info at the moment, but it will put back approval in the US by another 6 months or so. The EMA in Europe have accepted the application.
Read more : FDA refuse to file letter | Views : 1380 | Replies : 0


pseudo relapses after Campath

I had one high dose of Campath 2-3 years ago. I got ITP and could not have another dose. I have not had any major relapses since the treatment. However, I have had and am currently experiencing pseudo relapses where I have worsening symptoms and periods of increased disability, which come and go frequently. I am not sure if I should even report these to my neuro. It is hard to tell. HAs anyone experienced ...
Read more : pseudo relapses after Campath | Views : 2735 | Replies : 8


Withawal of campath

Apparently in the US and most of Europe, Sanofi are withdrawing the unlicensed use of Campath for MS treatment ie use outside of a recognised trial. Drs. will only be able to get it for named cancer patients. I think this starts in the US in November. This is in preparation for it to be licensed under Lemtrada once the EMA and FDA have looked at it.
Read more : Withawal of campath | Views : 1431 | Replies : 0


 

Login  •  Register


Statistics

Total posts 222337 • Total topics 23092 • Total members 14619


Contact us | Terms of Service